83P - Breast cancer management in an Indian oncology framework: Comparison with the standard guidelines

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Early Stage
Presenter Aakanksha Sharma
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors A. Sharma1, G. Parthasarathi1, C.B. Avinash2
  • 1Pharmacy Practice, JSS College of Pharmacy, Mysore, 570015 - Mysore/IN
  • 2Medical Oncology, Bharath Hospital and Institute of Oncology, 570017 - Mysore/IN



A study was conducted to assess the utilization pattern of anticancer drugs and comparing it with the standard guidelines.


This was a prospective study carried out for 18 months at an oncology speciality. All the newly diagnosed patients were enrolled. The relevant data was collected from medical records to evaluate the prescribing practice, patient/caregivers’ interviewed to complete any other relevant data. The prescriptions were reviewed in lieu of disease & tumor characteristics, chemotherapy selection & administration, prescribed anti-emetics in terms of selection, dose, dilution & administration to assess their compliance with the standard guidelines (NCCN).


92 patients corresponding to 129 prescriptions were evaluated. The study population comprised of early disease (63%), locally advanced (17%) and metastatic (7%) based on disease & tumor characteristics. 13% patients were planned for neoadjuvant therapy. The regimen followed in all these patients was anthracycline based with/without 5-Fluorouracil (5-FU). 35% had anthracycline along with 5-FU and 65% without it. Amongst the 5-FU containing regimens 27.5% had doxorubicin and 72.5% cases had epirubicin. The prescriptions without 5-FU were added with taxanes. 80% contained paclitaxel whereas 7% had docetaxel prescribed. It was observed 26% had hormone positive disease and were planned to be prescribed with tamoxifen or anastrazole. 11% were Her2/neu positive and planned to be given trastuzumab. Although the dosing of the chemotherapeutic agents was not according to BSA for the subsequent cycles but the selection was compliant in all the cases. 22% prescriptions had administration errors where the drug was not administered as prescribed. 31% anti-emetics prescriptions were in line with standards and rest were noncompliant. The noncompliance was observed in terms of selection of anti-emetics (46%); dose (31%); dilution (13%); and administration (10%).


The drug selection was as per the standard guidelines but noncompliance was seen in its administration. There were many deviations seen in the selection of anti-emetics from the standard guidelines; maybe due to the financial constraints of the patients.

Clinical trial indentification

Legal entity responsible for the study

Aakanksha Sharma




All authors have declared no conflicts of interest.